



VANUATU

Number of new cases

250

Number of deaths


151

Number of prevalent cases (5-year)

599


Statistics at a glance, 2022

| | Males | Females | Both sexes |
|--------------------------------------------------------------------|---------------------------|--------------------------------------|---------------------------------|
| Population | 163 052 | 158 782 | 321 834 |
| Incidence* | | | |
| Number of new cancer cases | 105 | 145 | 250 |
| Age-standardized incidence rate | 94.0 | 121.7 | 108.2 |
| Risk of developing cancer before the age of 75 years (cum. risk %) | 10.6 | 12.5 | 11.6 |
| Top 3 leading cancers (ranked by cases)** | Liver Prostate Lung | Breast Cervix uteri Thyroid | Breast Liver Cervix uteri |
| Mortality* | | | |
| Number of cancer deaths | 77 | 74 | 151 |
| Age-standardized mortality rate | 69.8 | 65.2 | 67.8 |
| Risk of dying from cancer before the age of 75 years (cum. risk %) | 8.2 | 7.0 | 7.7 |
| Top 3 leading cancers (ranked by deaths)** | Liver Lung Prostate | Cervix uteri Breast Colorectum | Liver Cervix uteri Lung |
| Prevalence* | | | |
| 5-year prevalent cases | 224 | 375 | 599 |



Top 5 most frequent cancers**


Males



| Rank | Cancer site | Number of cases | Percent |
|------|-------------|-----------------|---------|
| 1st | Liver | 21 | 20.0% |
| 2nd | Prostate | 20 | 19.0% |
| 3rd | Lung | 12 | 11.4% |
| 4th | Colorectum | 6 | 5.7% |
| 5th | NHL | 5 | 4.8% |
| - | Others | 41 | 39.0% |

Number of new cases in 2022, males, all ages


Females



| Rank | Cancer site | Number of cases | Percent |
|------|--------------|-----------------|---------|
| 1st | Breast | 37 | 25.5% |
| 2nd | Cervix uteri | 23 | 15.9% |
| 3rd | Thyroid | 19 | 13.1% |
| 4th | Corpus uteri | 10 | 6.9% |
| 5th | Colorectum | 7 | 4.8% |
| - | Others | 49 | 33.8% |

Number of new cases in 2022, females, all ages

Both sexes



| Rank | Cancer site | Number of cases | Percent |
|------|--------------|-----------------|---------|
| 1st | Breast | 37 | 14.8% |
| 2nd | Liver | 26 | 10.4% |
| 3rd | Cervix uteri | 23 | 9.2% |
| 4th | Thyroid | 22 | 8.8% |
| 5th | Prostate | 20 | 8.0% |
| - | Others | 122 | 48.8% |

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

| Cancer | New cases | | | | Deaths | | | | 5-year prevalence | |
|-------------------------------|------------|----------|----------|-------------|------------|----------|----------|------------|-------------------|---------------------|
| | Number | Rank | (%) | Cum.risk | Number | Rank | (%) | Cum.risk | Number | Prop. (per 100 000) |
| Breast | 37 | 1 | 14.8 | 3.1 | 11 | 5 | 7.3 | 0.74 | 99 | 62.4 |
| Liver | 26 | 2 | 10.4 | 1.5 | 24 | 1 | 15.9 | 1.5 | 42 | 13.1 |
| Cervix uteri | 23 | 3 | 9.2 | 1.8 | 18 | 2 | 11.9 | 1.4 | 62 | 39.1 |
| Thyroid | 22 | 4 | 8.8 | 0.95 | 5 | 9 | 3.3 | 0.40 | 62 | 19.3 |
| Prostate | 20 | 5 | 8.0 | 2.5 | 7 | 6 | 4.6 | 0.80 | 41 | 25.2 |
| Lung | 15 | 6 | 6.0 | 0.94 | 15 | 3 | 9.9 | 0.94 | 25 | 7.8 |
| Colorectum | 13 | 7 | 5.2 | 0.95 | 13 | 4 | 8.6 | 0.95 | 32 | 9.9 |
| NHL | 11 | 8 | 4.4 | 0.31 | 7 | 6 | 4.6 | 0.22 | 33 | 10.3 |
| Corpus uteri | 10 | 9 | 4.0 | 1.3 | 3 | 13 | 2.0 | 0.33 | 30 | 18.9 |
| Stomach | 7 | 10 | 2.8 | 0.48 | 7 | 6 | 4.6 | 0.48 | 14 | 4.4 |
| Leukaemia | 7 | 10 | 2.8 | 0.17 | 5 | 9 | 3.3 | 0.18 | 21 | 6.5 |
| Lip, oral cavity | 5 | 12 | 2.0 | 0.20 | 4 | 11 | 2.6 | 0.15 | 14 | 4.4 |
| Larynx | 4 | 13 | 1.6 | 0.14 | 4 | 11 | 2.6 | 0.14 | 12 | 3.7 |
| Bladder | 4 | 13 | 1.6 | 0.25 | 3 | 13 | 2.0 | 0.21 | 12 | 3.7 |
| Ovary | 3 | 15 | 1.2 | 0.18 | 2 | 15 | 1.3 | 0.14 | 9 | 5.7 |
| Testis | 2 | 16 | 0.80 | 0.14 | 0 | 20 | 0.00 | 0.00 | 6 | 3.7 |
| Salivary glands | 1 | 17 | 0.40 | 0.03 | 1 | 16 | 0.66 | 0.03 | 3 | 0.93 |
| Oesophagus | 1 | 17 | 0.40 | 0.04 | 1 | 16 | 0.66 | 0.04 | 2 | 0.62 |
| Pancreas | 1 | 17 | 0.40 | 0.07 | 1 | 16 | 0.66 | 0.07 | 1 | 0.31 |
| Penis | 1 | 17 | 0.40 | 0.00 | 0 | 20 | 0.00 | 0.00 | 2 | 1.2 |
| Multiple myeloma | 1 | 17 | 0.40 | 0.04 | 1 | 16 | 0.66 | 0.04 | 3 | 0.93 |
| Oropharynx | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Nasopharynx | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Hypopharynx | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Gallbladder | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Melanoma | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Mesothelioma | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Kaposi sarcoma | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Vulva | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Vagina | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Kidney | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| Brain CNS | 0 | 22 | 0.00 | 0.00 | 0 | 20 | 0.00 | 0.00 | 0 | 0.00 |
| All cancers | 250 | - | - | 11.6 | 151 | - | - | 7.7 | 599 | - |
| All cancers excl. NMSC | 250 | - | - | 11.6 | 151 | - | - | 7.7 | 599 | - |

Data source and methods

Incidence



Country-specific data source: No data
Method: No data: the rates are those of neighbouring countries or registries in the same area

Mortality

Country-specific data source: No data
Method: Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

